Please login to the form below

Not currently logged in
Email:
Password:

Disarm Therapeutics

This page shows the latest Disarm Therapeutics news and features for those working in and with pharma, biotech and healthcare.

Lilly buys biotech firm Disarm Therapeutics for $135m

Lilly buys biotech firm Disarm Therapeutics for $135m

Deal could eventually be worth up to $1.36bn. Eli Lilly is set to acquire private biotech company Disarm Therapeutics for an initial upfront payment of $135m, with a focus on ... Disarm’s focus is on the development of a new class of disease-modifying

Latest news

More from news
Approximately 1 fully matching, plus 0 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Blue Latitude Health

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...

Latest intelligence

Mistrust in medical research: a patient perspective
The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
Real-world evidence: breaking boundaries in rare disease
Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...
The heavy toll of COVID-19 on cancer patients
We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of...

Infographics